Evidence map›Paper›PMID 25065599›Full record

ArticleOncogene2015

Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.

A Kroiss, S Vincent, M Decaussin-Petrucci, E Meugnier, J Viallet, A Ruffion, F Chalmel, J Samarut, N Allioli

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Modulation of Immune Response toFrontiers in cellular and infection microbiology · 2021
    Article
  20. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.Frontiers in cell and developmental biology · 2021
    Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A KroissUniversité de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France.
S VincentUniversité de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France.
M Decaussin-Petrucci1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
E MeugnierLaboratoire CarMen, INSERM U1060, INRA1362, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Oullins, France.
J VialletIn Ovo, Institut Albert Bonniot, CRI INSERM/UJF U823, Université de Grenoble, La Tronche Cedex, France.
A Ruffion1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service d'Urologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
F ChalmelGERHM, INSERM U1085-Irset, Université Rennes 1, Rennes, France.
J Samarut1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service de Biochimie Biologie Moleculaire Sud, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
N Allioli1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Institut des Sciences Pharmaceutiques et Biologiques (ISPB)-Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
École Normale Supérieure de Lyon · FRUniversité Claude Bernard Lyon 1 · FRInserm · FRUniversité Joseph Fourier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase-quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound-healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (⩾8). Moreover, miR-135a expression is lower in invasive tumors, showing extraprostatic extension, as compared with intraprostatic localized tumors. In tumor relative to normal glands, we also showed a more frequently higher ROCK1 protein expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein expression, which could explain their invasion abilities. The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human PCa.

Indexed as

AdenocarcinomaAndrogensAnimalsBase SequenceCell Line, TumorCell MovementChick EmbryoDown-RegulationGene Expression Regulation, NeoplasticHeLa CellsHumansMaleMiceMice, SCIDMicroRNAsMolecular Sequence DataAndrogensMicroRNAsMIRN135 microRNA, humanrho-Associated KinasesROCK1 protein, humanROCK2 protein, human

Identifiers

PMID25065599
OpenAlexW2015317857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.